Galera Therapeutics Files 8-K
Ticker: GRTX · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1563577
Sentiment: neutral
Topics: material-definitive-agreement, financial-statements, 8-k
TL;DR
Galera Therapeutics filed an 8-K on 3/31/25, likely a material agreement or financial update.
AI Summary
On March 31, 2025, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes financial statements and exhibits. The report was filed on April 2, 2025.
Why It Matters
This 8-K filing signals a significant event for Galera Therapeutics, potentially involving a new agreement or financial update that could impact investors.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Numbers
- 001-39114 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-1454898 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- March 31, 2025 (date) — Date of earliest event reported
- April 2, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Galera Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before March 31, 2025.
What specific financial statements or exhibits are included with this 8-K filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided header information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 31, 2025.
What is Galera Therapeutics' principal executive office address?
Galera Therapeutics, Inc.'s principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What is the SEC file number for Galera Therapeutics?
The SEC file number for Galera Therapeutics, Inc. is 001-39114.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding Galera Therapeutics, Inc. (GRTX).